U.S. Artificial Intelligence in Biotechnology Market to Soar to $10.46 Billion by 2034, Growing at a Robust CAGR of 19.51%

Revolutionary AI Technologies Accelerate Biotechnology Innovations, Transforming Drug Discovery and Precision Medicine in the U.S.

The U.S. artificial intelligence in biotechnology market is projected to expand significantly, reaching an impressive valuation of approximately USD 10.46 billion by 2034, up from USD 2.10 billion in 2025. This dynamic growth is propelled by an accelerating CAGR of 19.51% over the forecast period from 2025 to 2034. Key market drivers include the widespread adoption of AI in drug discovery, precision medicine, and genomics, supported by strong research and development investments and a robust technological infrastructure in the U.S.

U.S. AI in Biotechnology Market Key Insights

• The U.S. AI in biotechnology market is valued at USD 2.10 billion in 2025, poised to achieve nearly USD 10.46 billion by 2034, growing at a CAGR of 19.51%.

• North America, led by the U.S., dominates the global AI biotechnology space due to substantial funding and cutting-edge infrastructure.

• AI-driven drug discovery and genomics are the primary growth segments, with predictive modeling witnessing rapid adoption.

• Leading players include Recursion Pharmaceuticals, Insilico Medicine, Roche, NVIDIA, Google, Microsoft, and Johnson & Johnson.

• The sector benefits strongly from government support, private investments, and collaborations bridging biotechnology and technology firms.

Market Revenue Breakdown and Segmentation

The market segmentation spans by technology (machine learning, deep learning), by application (drug discovery, predictive modeling, genomics), and by end-use (medical biotechnology, biopharmaceutical companies). In 2025, the highest revenue shares arise from medical biotechnology and predictive modeling, with predictive analytics deploying AI to accelerate patient diagnosis and treatment efficacy.

Artificial intelligence is a pivotal catalyst in reshaping biotechnology research and innovation in the United States. AI-powered algorithms streamline the drug discovery process by analyzing large-scale genomic, proteomic, and clinical datasets to predict molecular interactions and identify promising drug candidates with unprecedented speed and accuracy. This predictive capacity drastically reduces the dependency on trial-and-error methods, accelerating time-to-market and lowering development costs.

Moreover, AI technologies such as machine learning, computer vision, and generative AI models are extensively integrated into personalized medicine, enabling tailored treatments based on individual genetic profiles. This enhances patient outcomes while promoting efficient clinical trial designs and optimized therapeutic interventions.

What Factors Are Driving Growth in the U.S. AI Biotechnology Market?

Multiple factors fuel the rapid growth of AI in biotechnology within the U.S.:

• Robust R&D Investments: Substantial investment from biopharma giants and tech companies boosts AI infrastructure and innovative projects.

• Increasing Demand for Personalized Medicine: AI’s capability to enable genomic mapping and biomarker discovery aligns with the growing precision medicine trend.

• Government and Industry Collaborations: Supportive regulatory frameworks and partnerships between technology firms and biotech companies fuel AI adoption.

• Technological Advancements: Breakthroughs in generative AI, high-content imaging, and automation enhance drug development efficiency.

U.S. Artificial Intelligence in Biotechnology Market Scope

What Opportunities and Trends Are Emerging in AI-Driven Biotechnology?

How is AI transforming traditional drug discovery and development?
AI accelerates identification of drug targets, simulates biological processes, and predicts drug effects, reducing development timelines and costs.

What new trends are shaping AI applications in biotechnology?
Predictive modeling, generative AI for molecule design, AI-driven clinical trial optimization, and AI-enabled personalized therapies are key emerging trends.

Are there specific sectors benefiting most from AI integration?
Medical biotechnology, especially precision medicine and regenerative therapies, along with biopharma companies focused on innovative drug development, see significant gains.

U.S. Artificial Intelligence in Biotechnology Market Regional and Segmentation Analysis

The U.S. leads the North American AI biotechnology market, driven by high investments, advanced AI research facilities, and a vibrant ecosystem uniting pharmaceutical and technology sectors. Regionally, hubs like Silicon Valley, Boston, and Salt Lake City are central nodes for AI-driven biotech innovation.

Segmentation highlights

• By Technology: Machine learning and deep learning dominate, with growing emphasis on generative AI and computer vision.

• By Application: Drug target identification and predictive modeling are prominent, enhancing clinical trial success rates and therapeutic efficiencies.

• End-User Focus: Medical biotechnology and pharmaceutical industries invest heavily in AI applications for next-generation therapies.

Leading Companies and Latest Innovations

Top U.S. companies spearheading AI in biotechnology include:

• Recursion Pharmaceuticals: Leveraging AI and automation to expedite drug candidate discovery and clinical development with proprietary biological image datasets.

• Insilico Medicine: Pioneering generative AI for novel drug target discovery and AI-first drug design platforms.

• Roche, NVIDIA, Google, Microsoft, and Johnson & Johnson actively invest and collaborate on AI-biotech innovations.

Notable breakthroughs include:

• Recursion’s launch of next-generation AI-driven platforms integrating generative AI for molecule design (2025).

• Insilico’s successful Phase I trial of an AI-discovered anti-fibrotic drug and expanded AI model partnerships (2023-2025).

• Strategic collaborations between AI and biotech leaders focusing on oncology, genomics, and bio-simulation.

Challenges and Cost Pressures in AI Biotechnology

Despite promising growth, challenges remain in the form of high research and development expenditures, regulatory complexities, and competitive pressures from emerging AI-biotech startups. Additionally, data governance, integration complexities, and the need for skilled AI-biotech talent pose hurdles for sustained innovation.

Case Study: Recursion Pharmaceuticals

Recursion Pharmaceuticals exemplifies the AI impact on biotechnology, having built one of the largest biological image datasets worldwide. Their AI-powered experimental biology lab uses deep learning and computer vision for drug candidate screening, accelerating preclinical research across multiple therapeutic areas such as oncology and rare genetic disorders. This approach dramatically shortens timelines for clinical development while improving success probabilities due to data-driven decision-making.

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7102

You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344

• Author
• Recent Posts

Rohan

Principal Consultant at Market Stats Insight

Rohan Patil is a seasoned Healthcare Principal Consultant at Market Stats Insight and Precedence Research, with more than 5 years of experience in market intelligence and strategic insights. Holding a BSc in Biotechnology and an MBA in Marketing, he combines scientific expertise with business acumen to deliver data-driven analysis. Rohan specializes in the medical device sector and closely tracks innovations shaping the future of healthcare. His research helps global clients identify growth opportunities, assess risks, and stay competitive in a rapidly evolving market landscape.

Latest posts by Rohan (see all)

• Battery Swapping Market Size to Touch USD 24.74 Billion by 2035 - March 5, 2026
• Dental Air Polishing System Market Size to Reach USD 1603.54 Million by 2035 - March 4, 2026
• Cryoballoon Ablation System Market Size to Surpass USD 2.49 Billion by 2035, Propelled by 5.70% Growth in Minimally Invasive Cardiac Care - March 2, 2026